Endocarditis Market Global and Regional Research Report 2025-2035 | AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 05 2025
0mins
Source: Yahoo Finance
Endocarditis Overview: Endocarditis, an infection of the heart's inner lining caused by bacteria, is increasing due to factors like healthcare-associated infections and an aging population. Advances in diagnostic imaging and AI-assisted echocardiography are enhancing detection and treatment outcomes, although challenges such as antimicrobial resistance remain.
Market Insights: North America leads the endocarditis market, driven by advanced healthcare systems, while the Asia-Pacific region shows rapid growth due to rising cardiovascular cases and increased healthcare investments. Key players like Pfizer and Teva Pharmaceutical are innovating in this sector, addressing both demand drivers and limitations in treatment.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.100
Low
24.00
Averages
28.56
High
35.00
Current: 26.100
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
